Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Pharmaceutical Medicine Pub Date : 2024-07-01 Epub Date: 2024-06-28 DOI:10.1007/s40290-024-00531-0
Cecilia Petrus, Holly Lam
{"title":"Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.","authors":"Cecilia Petrus, Holly Lam","doi":"10.1007/s40290-024-00531-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To optimize cost effectiveness, engagement, reach, inclusivity, insight quality and quantity, and participant satisfaction of pharmaceutical meetings such as advisory boards, the organizers have to carefully weigh the pros and cons of the available meeting formats (in-person, synchronous virtual, asynchronous, hybrid). While budgets and organizer preferences are typically key considerations, participants' preferences are rarely factored into this decision. Hence, the objectives of this study were to gain a better understanding of participants' preferences for meeting format, frequency, and updates.</p><p><strong>Methods: </strong>Between September 1, 2022, and December 31, 2023, health care providers (HCPs) participating in asynchronous advisory board touchpoints on a proprietary virtual platform were asked to answer between 1-4 survey questions, selected at the pharmaceutical organizers' discretion.</p><p><strong>Results: </strong>A total of 443 HCPs answered the survey. Among respondents, 76.0% preferred meetings with a virtual component. Overall, the most popular meeting approach was a combination of synchronous and asynchronous virtual meetings over time (34.6%). The preference for hybrid meetings increased from 14.3 to 27.3% between 2022 and 2023. The preferred meeting frequency was 2-3 times a year (39.2%), followed by quarterly (33.2%). According to the respondents, the most important benefits of virtual over in-person meetings include: (i) superior convenience and flexibility (81.0%), (ii) avoidance of time off work and away from patients (62.3%), (iii) the low environmental impact and carbon footprint (32.5%).</p><p><strong>Conclusions: </strong>Although these findings are preliminary and from a small dataset, they highlight the importance of customizing each pharmaceutical meeting or program with the target audience in mind.</p>","PeriodicalId":19778,"journal":{"name":"Pharmaceutical Medicine","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40290-024-00531-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To optimize cost effectiveness, engagement, reach, inclusivity, insight quality and quantity, and participant satisfaction of pharmaceutical meetings such as advisory boards, the organizers have to carefully weigh the pros and cons of the available meeting formats (in-person, synchronous virtual, asynchronous, hybrid). While budgets and organizer preferences are typically key considerations, participants' preferences are rarely factored into this decision. Hence, the objectives of this study were to gain a better understanding of participants' preferences for meeting format, frequency, and updates.

Methods: Between September 1, 2022, and December 31, 2023, health care providers (HCPs) participating in asynchronous advisory board touchpoints on a proprietary virtual platform were asked to answer between 1-4 survey questions, selected at the pharmaceutical organizers' discretion.

Results: A total of 443 HCPs answered the survey. Among respondents, 76.0% preferred meetings with a virtual component. Overall, the most popular meeting approach was a combination of synchronous and asynchronous virtual meetings over time (34.6%). The preference for hybrid meetings increased from 14.3 to 27.3% between 2022 and 2023. The preferred meeting frequency was 2-3 times a year (39.2%), followed by quarterly (33.2%). According to the respondents, the most important benefits of virtual over in-person meetings include: (i) superior convenience and flexibility (81.0%), (ii) avoidance of time off work and away from patients (62.3%), (iii) the low environmental impact and carbon footprint (32.5%).

Conclusions: Although these findings are preliminary and from a small dataset, they highlight the importance of customizing each pharmaceutical meeting or program with the target audience in mind.

与医疗服务提供者一起策划有效且有吸引力的咨询委员会和其他小范围会议的注意事项:参与者偏好的重要性。
背景:为了优化咨询委员会等医药会议的成本效益、参与度、覆盖面、包容性、见解的质量和数量以及与会者的满意度,组织者必须仔细权衡现有会议形式(面对面、同步虚拟、异步、混合)的利弊。虽然预算和组织者的偏好通常是主要考虑因素,但与会者的偏好却很少被纳入这一决策中。因此,本研究旨在更好地了解与会者对会议形式、频率和更新的偏好:方法:2022 年 9 月 1 日至 2023 年 12 月 31 日期间,参加专有虚拟平台上异步咨询委员会接触点的医疗保健提供者(HCP)被要求回答 1-4 个调查问题,这些问题由制药组织者自行决定:共有 443 名 HCP 回答了调查问题。在受访者中,76.0% 的人倾向于采用虚拟会议形式。总体而言,最受欢迎的会议方式是一段时间内同步和异步虚拟会议的组合(34.6%)。在 2022 年至 2023 年期间,对混合会议的偏好从 14.3%增至 27.3%。首选的会议频率是每年 2-3 次(39.2%),其次是每季度一次(33.2%)。受访者认为,与面对面会议相比,虚拟会议最重要的优势包括(i) 更好的便利性和灵活性(81.0%),(ii) 避免请假和远离病人(62.3%),(iii) 对环境影响小,碳足迹小(32.5%):尽管这些研究结果只是初步的,而且来自一个小规模的数据集,但它们强调了根据目标受众定制每次制药会议或计划的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Medicine
Pharmaceutical Medicine PHARMACOLOGY & PHARMACY-
CiteScore
5.10
自引率
4.00%
发文量
36
期刊介绍: Pharmaceutical Medicine is a specialist discipline concerned with medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution and pricing of medicines, drug-device and drug-diagnostic combinations. The Journal disseminates information to support the community of professionals working in these highly inter-related functions. Key areas include translational medicine, clinical trial design, pharmacovigilance, clinical toxicology, drug regulation, clinical pharmacology, biostatistics and pharmacoeconomics. The Journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on topical issues.Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by PRISMA statement.Original research articles reporting the results of well-designed studies with a strong link to wider areas of clinical research.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pharmaceutical Medicine may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信